KR101317100B1 - 세포-침투성 펩티드로서 유용한 펩티드 - Google Patents

세포-침투성 펩티드로서 유용한 펩티드 Download PDF

Info

Publication number
KR101317100B1
KR101317100B1 KR1020087015786A KR20087015786A KR101317100B1 KR 101317100 B1 KR101317100 B1 KR 101317100B1 KR 1020087015786 A KR1020087015786 A KR 1020087015786A KR 20087015786 A KR20087015786 A KR 20087015786A KR 101317100 B1 KR101317100 B1 KR 101317100B1
Authority
KR
South Korea
Prior art keywords
peptide
peptides
seq
delete delete
nucleic acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020087015786A
Other languages
English (en)
Korean (ko)
Other versions
KR20080091120A (ko
Inventor
롤란드 브록
라이너 피셔
마리올라 포틴-믈렉체
한스외르크 후프나겔
노르베르트 빈드하브
Original Assignee
에보니크 룀 게엠베하
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 에보니크 룀 게엠베하 filed Critical 에보니크 룀 게엠베하
Publication of KR20080091120A publication Critical patent/KR20080091120A/ko
Application granted granted Critical
Publication of KR101317100B1 publication Critical patent/KR101317100B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/644—Transferrin, e.g. a lactoferrin or ovotransferrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/088—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins conjugates with carriers being peptides, polyamino acids or proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/79—Transferrins, e.g. lactoferrins, ovotransferrins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Dermatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
KR1020087015786A 2005-12-30 2006-10-25 세포-침투성 펩티드로서 유용한 펩티드 Active KR101317100B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP05028755.6 2005-12-30
EP05028755 2005-12-30
PCT/EP2006/010271 WO2007076904A1 (en) 2005-12-30 2006-10-25 Peptides useful as cell-penetrating peptides

Publications (2)

Publication Number Publication Date
KR20080091120A KR20080091120A (ko) 2008-10-09
KR101317100B1 true KR101317100B1 (ko) 2013-10-15

Family

ID=37491778

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020087015786A Active KR101317100B1 (ko) 2005-12-30 2006-10-25 세포-침투성 펩티드로서 유용한 펩티드

Country Status (16)

Country Link
US (3) US20100061932A1 (enExample)
EP (1) EP1966240B3 (enExample)
JP (1) JP5264502B2 (enExample)
KR (1) KR101317100B1 (enExample)
CN (1) CN101395180B (enExample)
AT (1) ATE501169T1 (enExample)
AU (1) AU2006332193B2 (enExample)
BR (1) BRPI0620806B8 (enExample)
CA (1) CA2646833C (enExample)
DE (1) DE602006020617D1 (enExample)
ES (1) ES2361621T7 (enExample)
IL (1) IL192131A (enExample)
MX (1) MX2008008548A (enExample)
PL (1) PL1966240T6 (enExample)
SI (1) SI1966240T1 (enExample)
WO (1) WO2007076904A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101647804B1 (ko) * 2015-06-24 2016-08-11 한국과학기술연구원 신규 세포투과 펩타이드 및 이의 용도

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102005051366A1 (de) 2005-10-25 2007-04-26 Degussa Gmbh Drug Delivery Systeme
EP2050461A1 (en) 2007-10-19 2009-04-22 PharmaSurgics in Sweden AB Peptides based on the sequence of human lactoferrin and their use
EP2090584A1 (en) * 2008-02-13 2009-08-19 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Identification of a novel cysteine-rich cell penetrating peptide
RU2470666C2 (ru) * 2008-02-28 2012-12-27 Торэй Индастриз, Инк. Фармацевтическая композиция для трансназального введения
CN102869384B (zh) 2009-06-22 2016-01-13 伯纳姆医学研究所 使用带有c-端元件的肽和蛋白质的方法和组合物
JP5818319B2 (ja) * 2009-12-14 2015-11-18 国立大学法人北海道大学 脂質膜構造体に細胞透過能を付与および／または脂質膜構造体の細胞透過能を増強するペプチド、ならびにそれらペプチドと結合した脂質を構成脂質として含む、細胞透過能を有するまたは細胞透過能が増強された脂質膜構造体
WO2011084061A1 (en) 2010-01-08 2011-07-14 Universitair Medisch Centrum St. Radboud Cpp (cell penetrating peptide) and its uses
FR2955773B1 (fr) * 2010-02-01 2017-05-26 Commissariat Energie Atomique Complexe moleculaire de ciblage des antigenes vers les cellules presentatrices d'antigene et ses applications pour la vaccination
US9724422B2 (en) * 2010-11-26 2017-08-08 Evonik Roehm Gmbh Human lactoferrin derived peptide for use as an antigen masking agent
CN102174078A (zh) * 2011-01-10 2011-09-07 中国药科大学 肿瘤细胞选择性穿膜肽的应用
CN102091036A (zh) * 2011-01-10 2011-06-15 中国药科大学 一种含有抗肿瘤药物的复合脂质体及其制备方法和用途
CN102153629B (zh) * 2011-01-20 2013-07-24 华中科技大学 一种短肽及其应用
WO2012118778A1 (en) 2011-02-28 2012-09-07 Sanford-Burnham Medical Research Institute Truncated car peptides and methods and compositions using truncated car peptides
EP2715291A4 (en) 2011-05-31 2015-10-21 Airware Inc NON-DISPERSIVE GAS SENSORS WITH ABSORPTION INFRARED ABSORPTION (NDIR)
US10179801B2 (en) 2011-08-26 2019-01-15 Sanford-Burnham Medical Research Institute Truncated LYP-1 peptides and methods and compositions using truncated LYP-1 peptides
CN102988295B (zh) * 2011-09-09 2015-07-29 复旦大学 一种穿膜肽修饰的纳米粒及其制备方法
CN102993296A (zh) * 2011-09-14 2013-03-27 广州格拉姆生物科技有限公司 牛乳铁蛋白肽及其制备方法
WO2013052058A1 (en) * 2011-10-07 2013-04-11 Morehouse School Of Medicine Antimicrobial compositions and methods of use thereof
US8669226B2 (en) 2011-10-07 2014-03-11 Morehouse School Of Medicine Antimicrobial compositions and methods of use thereof
US12083158B2 (en) 2011-10-07 2024-09-10 Morehouse School Of Medicine Antibacterial compositions, methods of making and use thereof
DE102011055229A1 (de) 2011-11-10 2013-05-16 Evonik Degussa Gmbh Verfahren zur Bereitstellung von Regelleistung mit einem Energiespeicher unter Ausnutzung von Toleranzen bei der Bestimmung der Frequenzabweichung
DE102011055231A1 (de) * 2011-11-10 2013-05-16 Evonik Industries Ag Verfahren zur Bereitstellung von Regelleistung
US9259483B2 (en) 2011-11-24 2016-02-16 Positec Power Tools (Suzhou) Co Ltd Peptide sequence design and use thereof for peptide-mediated siRNA delivery
CN103169982B (zh) * 2011-12-23 2015-05-20 中国科学院上海药物研究所 生物活性肽修饰的纳米银及其制备方法和用途
CN103382217B (zh) * 2012-12-11 2015-05-27 任发政 穿膜肽和药物组合物及其制备方法和应用
US9642895B2 (en) 2013-08-12 2017-05-09 3M Innovative Properties Company Peptides for enhancing transdermal delivery
WO2015075747A1 (en) * 2013-11-19 2015-05-28 Council Of Scientific And Industrial Research Cell-penetrating peptide for biomolecule delivery
WO2015089487A1 (en) 2013-12-12 2015-06-18 Life Technologies Corporation Membrane-penetrating peptides to enhance transfection and compositions and methods for using same
CN103784406A (zh) * 2014-01-20 2014-05-14 同济大学 一种偶联穿膜肽和mmp酶切位点的纳米颗粒
ES2767501T3 (es) * 2014-05-28 2020-06-17 Evonik Operations Gmbh Nanopartícula
US10793603B2 (en) * 2015-02-27 2020-10-06 Josho Gakuen Educational Foundation Polysaccharide derivative having membrane-permeable peptide chain
CN108456254B (zh) * 2017-02-20 2021-06-01 中国科学院上海药物研究所 一种tcs-穿膜肽-肿瘤蛋白酶底物肽融合蛋白、其制备方法和用途
EP3628047A1 (en) 2017-05-02 2020-04-01 Sanford Burnham Prebys Medical Discovery Institute Tumor associated monocyte/macrophage binding peptide and methods of use thereof
CN108101966B (zh) * 2017-12-26 2020-10-27 暨南大学 基于细胞穿膜肽的氧化还原敏感多肽及其在疫苗载体中的应用
EP3790534B1 (en) 2018-05-08 2023-08-30 Evonik Operations GmbH Nanoparticle comprising a bio-resorbable polyester, a hydrophilic polymer and an acylated human lactoferrin-derived peptide
CN111499759B (zh) * 2019-01-31 2022-12-20 上海科技大学 一种具有细胞穿膜性的锌指蛋白-乳铁蛋白融合蛋白质及其制备与应用
EP3921329A1 (en) 2019-02-04 2021-12-15 University of Tartu Bi-specific extracellular matrix binding peptides and methods of use thereof
CN110078834B (zh) * 2019-05-05 2021-07-30 华中科技大学 一种类短肽、辅助透膜剂及其应用
CN112426438B (zh) * 2019-11-14 2023-12-05 上海鑫湾生物科技有限公司 用于调控酸性环境免疫应答的组合物、其制备方法和用途
BR112022019370A2 (pt) * 2020-03-27 2022-11-29 Alastin Skincare Inc Composições e métodos relativos à pigmentação
IL315874A (en) 2022-03-30 2024-11-01 Evonik Operations Gmbh Formulations consisting of cationic lipids and poly(lactic-co-glycolic acid) for delivery of polynucleotides to cells
EP4601700A1 (en) * 2022-10-13 2025-08-20 Stichting Radboud universitair medisch centrum A complex comprising a cargo and a targeting moiety binding intelectin-1
CN120641131A (zh) 2022-12-01 2025-09-12 耶鲁大学 用于细胞内有效载荷递送的刺激反应性无痕工程化平台

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000004132A1 (en) 1998-07-15 2000-01-27 Samyang Genex Corporation Mass production method of lactoferrin polypeptide from yeast and useful microorganism thereof

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5633076A (en) * 1989-12-01 1997-05-27 Pharming Bv Method of producing a transgenic bovine or transgenic bovine embryo
KR970002255B1 (ko) 1990-06-11 1997-02-26 넥스스타 파아마슈티컬드, 인크. 핵산 리간드
JP2818056B2 (ja) 1990-09-07 1998-10-30 森永乳業株式会社 抗菌性ペプチドおよび抗菌剤
JP3207535B2 (ja) * 1992-08-07 2001-09-10 森永乳業株式会社 抗酸化剤
JP3312946B2 (ja) * 1993-03-04 2002-08-12 雪印乳業株式会社 ウイルス感染・増殖抑制剤
JP2001504448A (ja) 1996-08-30 2001-04-03 フュルステ，イェンス，ペーター 核酸の鏡面対称選択および進化
US5849902A (en) 1996-09-26 1998-12-15 Oligos Etc. Inc. Three component chimeric antisense oligonucleotides
US6958239B2 (en) 1996-11-21 2005-10-25 Oligos Etc Inc. Three component chimeric antisense oligonucleotides
DE19742706B4 (de) 1997-09-26 2013-07-25 Pieris Proteolab Ag Lipocalinmuteine
SE9804614A0 (en) * 1998-07-06 2000-01-07 A+ Science Invest Ab New peptides and use thereof
JP3681982B2 (ja) * 1998-07-15 2005-08-10 サムヤン ジェネックス コーポレイション 酵母からラクトフェリンポリペプチドを大量生産する方法及びそれに有用な微生物菌株
GB9818938D0 (en) * 1998-08-28 1998-10-21 Alpharma As Bioactive peptides
DE19956568A1 (de) 1999-01-30 2000-08-17 Roland Kreutzer Verfahren und Medikament zur Hemmung der Expression eines vorgegebenen Gens
US6399570B1 (en) * 1999-02-05 2002-06-04 Agennix, Inc. Antimicrobial/endotoxin neutralizing polypeptide
EP1309726B2 (en) 2000-03-30 2018-10-03 Whitehead Institute For Biomedical Research Rna sequence-specific mediators of rna interference

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000004132A1 (en) 1998-07-15 2000-01-27 Samyang Genex Corporation Mass production method of lactoferrin polypeptide from yeast and useful microorganism thereof

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101647804B1 (ko) * 2015-06-24 2016-08-11 한국과학기술연구원 신규 세포투과 펩타이드 및 이의 용도

Also Published As

Publication number Publication date
CN101395180A (zh) 2009-03-25
US9403884B2 (en) 2016-08-02
MX2008008548A (es) 2008-09-10
EP1966240A1 (en) 2008-09-10
US20160151504A1 (en) 2016-06-02
AU2006332193B2 (en) 2012-06-28
JP5264502B2 (ja) 2013-08-14
AU2006332193A1 (en) 2007-07-12
CN101395180B (zh) 2016-06-22
WO2007076904A1 (en) 2007-07-12
PL1966240T3 (pl) 2011-08-31
EP1966240B3 (en) 2011-12-28
BRPI0620806B1 (pt) 2017-12-05
CA2646833A1 (en) 2007-07-12
ES2361621T3 (es) 2011-06-20
CA2646833C (en) 2019-07-30
JP2009521908A (ja) 2009-06-11
BRPI0620806B8 (pt) 2022-07-05
US20130108662A1 (en) 2013-05-02
BRPI0620806A2 (pt) 2011-11-22
IL192131A (en) 2011-10-31
IL192131A0 (en) 2008-12-29
KR20080091120A (ko) 2008-10-09
EP1966240B1 (en) 2011-03-09
ES2361621T7 (es) 2012-06-14
ATE501169T1 (de) 2011-03-15
SI1966240T1 (sl) 2011-06-30
PL1966240T6 (pl) 2012-05-31
US20100061932A1 (en) 2010-03-11
DE602006020617D1 (de) 2011-04-21

Similar Documents

Publication Publication Date Title
KR101317100B1 (ko) 세포-침투성 펩티드로서 유용한 펩티드
JP7386161B2 (ja) 腫瘍ホーミング及び細胞透過性ペプチド免疫抗がん剤複合体、ならびにそれらの使用方法
KR101590674B1 (ko) 세포-투과 펩티드 및 이의 용도
TWI655287B (zh) 穿膜胜肽以及包含該胜肽之共軛物及組成物（三）
JP6077543B2 (ja) ペプチド
JP5902679B2 (ja) ＩＬ−４Ｒαに結合する涙液リポカリンムテイン
WO2012090150A2 (en) New cell-penetrating peptides and uses thereof
AU2011244107A1 (en) Peptide derivatives, preparation thereof and uses thereof as vectors
KR20150100655A (ko) 혈액 뇌 장벽 수송을 위한 폴리펩티드
EP2537858A1 (en) Small efficient cell penetrating peptides derived from the scorpion toxin maurocalcine
KR20130111237A (ko) 인슐린-유사 성장 인자 1 수용체 결합 펩티드
HK1180232B (en) Cell-penetrating peptides and uses thereof
HK1180232A (en) Cell-penetrating peptides and uses thereof

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20080627

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20111025

Comment text: Request for Examination of Application

PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20130513

Patent event code: PE09021S01D

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 20130829

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20131002

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20131002

End annual number: 3

Start annual number: 1

PG1601 Publication of registration
FPAY Annual fee payment

Payment date: 20160922

Year of fee payment: 4

PR1001 Payment of annual fee

Payment date: 20160922

Start annual number: 4

End annual number: 4

FPAY Annual fee payment

Payment date: 20170922

Year of fee payment: 5

PR1001 Payment of annual fee

Payment date: 20170922

Start annual number: 5

End annual number: 5

FPAY Annual fee payment

Payment date: 20180921

Year of fee payment: 6

PR1001 Payment of annual fee

Payment date: 20180921

Start annual number: 6

End annual number: 6

PR1001 Payment of annual fee

Payment date: 20190920

Start annual number: 7

End annual number: 7

PR1001 Payment of annual fee

Payment date: 20200924

Start annual number: 8

End annual number: 8

PR1001 Payment of annual fee

Payment date: 20210923

Start annual number: 9

End annual number: 9

PR1001 Payment of annual fee

Payment date: 20220923

Start annual number: 10

End annual number: 10